Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca 
Welcome,         Profile    Billing    Logout  
 32 Diseases   9 Trials   9 Trials   795 News 


«12345678910111213»
  • ||||||||||  Jakafi oral (ruxolitinib) / Novartis, Incyte, Xeljanz (tofacitinib) / Pfizer
    Clinical, Journal:  New and Emerging Therapies for Pediatric Atopic Dermatitis. (Pubmed Central) -  Oct 31, 2019   
    Other drugs with potential include the aryl hydrocarbon receptor modulating agent tapinarof, the IL-4/IL-13 antagonists lebrikizumab and tralokinumab, and the IL-31Rα antagonist nemolizumab. In this review, new and emerging AD therapies will be discussed along with their mechanisms of action and their potential based on clinical study data.
  • ||||||||||  Review, Journal:  What's New in Atopic Dermatitis. (Pubmed Central) -  Jul 4, 2019   
    Nevertheless, because not all patients respond to dupilumab and AD has a heterogeneous phenotype, more treatment options are much needed. This article reviews recent and exciting developments in AD, because ongoing or pipeline clinical trials for AD will ultimately expand and redefine a novel treatment paradigm for this common disease.
  • ||||||||||  tralokinumab (CAT 354) / Leo Pharma, AstraZeneca
    Clinical, Journal:  Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. (Pubmed Central) -  Jun 26, 2019   
    P2, P3
    Further trials have assessed the ability of tralokinumab to reduce oral corticosteroid use (TROPOS; NCT02281357) and determined its mechanistic effects (MESOS; NCT02449473). An open-label study in Japanese individuals (NCT02902809) assessed the long-term safety and tolerability of tralokinumab in this population.
  • ||||||||||  anrukinzumab (IMA-638) / Pfizer, tralokinumab (CAT 354) / Leo Pharma, AstraZeneca
    Review, Journal:  The role of interleukin-13 in chronic inflammatory intestinal disorders. (Pubmed Central) -  Jun 3, 2019   
    Failure of the anti-IL-13 monoclonal antibodies tralokinumab and anrukinzumab in UC patients in clinical trials support the absence of a role for IL-13 in UC. This review deals with IL-13 in several experimental colitis models -such as oxazolone-, trinitrobenzene sulfonic acid- or dextran sodium sulphate-induced colitis- and chronic intestinal inflammatory disorders -including celiac disease, UC and Crohn's disease-, and it also highlights the attempts to modulate IL-13 as therapeutic tool.
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Enrollment closed:  Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5) (clinicaltrials.gov) -  May 23, 2019   
    P2,  N=212, Active, not recruiting, 
    This review deals with IL-13 in several experimental colitis models -such as oxazolone-, trinitrobenzene sulfonic acid- or dextran sodium sulphate-induced colitis- and chronic intestinal inflammatory disorders -including celiac disease, UC and Crohn's disease-, and it also highlights the attempts to modulate IL-13 as therapeutic tool. Recruiting --> Active, not recruiting
  • ||||||||||  Enrollment change:  Molecular Signatures in Inflammatory Skin Disease (clinicaltrials.gov) -  Sep 25, 2018   
    P=N/A,  N=200, Recruiting, 
    Trial primary completion date: Sep 2018 --> Mar 2019 N=50 --> 200
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Trial completion, Trial completion date, Trial primary completion date:  A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata (clinicaltrials.gov) -  Aug 22, 2018   
    P2,  N=22, Completed, 
    N=50 --> 200 Recruiting --> Completed | Trial completion date: Apr 2018 --> Nov 2017 | Trial primary completion date: Apr 2018 --> Nov 2017
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Trial completion date, Trial primary completion date, Monotherapy:  Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) (clinicaltrials.gov) -  Jul 17, 2018   
    P3,  N=780, Active, not recruiting, 
    Trial completion date: Nov 2019 --> Aug 2019 | Trial primary completion date: Nov 2019 --> Sep 2018 Trial completion date: Jun 2020 --> Nov 2019 | Trial primary completion date: Feb 2020 --> Sep 2018
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Trial completion, Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) -  Feb 20, 2018   
    P3,  N=28, Completed, 
    Initiation date: Feb 2018 --> Feb 2018 Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Jan 2018 | Trial completion date: May 2018 --> Jan 2018
  • ||||||||||  Adbry (tralokinumab-ldrm) / LEO Pharma, AstraZeneca
    Trial primary completion date:  A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma (clinicaltrials.gov) -  Nov 27, 2017   
    P3,  N=28, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2018 --> Jan 2018 | Trial completion date: May 2018 --> Jan 2018 Trial primary completion date: Oct 2017 --> May 2018